Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...
Zycubo is a copper replacement therapy administered via subcutaneous injection to bypass impaired GI absorption in patients with Menkes disease.
The US regulator has approved Sentynl Therapeutics Zycubo (copper histidinate; formerly known as CUTX-101) as a treatment for ...
As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...
Investing.com -- The U.S. Food and Drug Administration (FDA) approved Zycubo (copper histidinate) injection on Monday as the ...
Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg ...
Atacicept, a novel dual inhibitor of BAFF and APRIL, receives FDA Priority Review for IgA nephropathy treatment in adults.
Self-administered injectable contraceptives have been available in the United States for more than two decades, yet a new ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...
Oxford University Hospitals launches UK arm of FORTIFY trial, testing orticumab for coronary inflammation in heart attack patients.
A new drug application (NDA) has been submitted to the FDA seeking approval of rusfertide, an investigational hepcidin ...
Delgocitinib cream and dupilumab have similar efficacy at 16 weeks of treatment in patients with moderate to severe atopic hand eczema.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback